Furthermore, we demonstrated that the protectory effect of CD38 deficiency on AngII-induced AAA was associated with the alleviation of vascular remodeling including the inhibition of the phenotype switch and the reduction of the infiltration of inflammatory cells, suggesting that CD38 may be a potential therapeutic target for the prevention and treatment of AAA formation. Here, CD38 is linked to triple-A syndrome.